Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

BioInvent International

29.70 SEK

-3.10 %

Less than 1K followers

BINV

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-3.10 %
-19.40 %
-18.18 %
-6.16 %
-22.86 %
-34.29 %
-28.52 %
-24.43 %
-96.88 %

BioInvent International is a biotechnology company focused on the development of innovative antibody therapies for cancer treatment. The company researches new treatments that can improve patient outcomes and quality of life. The company operates globally with a presence in international markets. BioInvent International was founded in 1983 and is headquartered in Lund.

Read more
Market cap
1.95B SEK
Turnover
2.12M SEK
Revenue
44.69M
EBIT %
-1,054.06 %
P/E
-
Dividend yield-%
-
Financial calendar
29.10
2025

Interim report Q3'25

All
Webcasts
Press releases
ShowingAll content types
Regulatory press release9/2/2025, 8:10 AM

BioInvent Announces Board of Directors Update

BioInvent International
Press release8/27/2025, 12:33 PM

BioStock: BioInvent expands on its strategic portfolio shift

BioInvent International
Press release8/27/2025, 10:35 AM

Redeye: BioInvent Q2 2025 - Narrowed Focus on BI-1206 and BI-1808

BioInvent International

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release8/26/2025, 6:30 AM

BioInvent International AB: Interim Report January – June 2025

BioInvent International
Regulatory press release8/26/2025, 6:29 AM

BioInvent Announces Strategic Changes in Portfolio to Accelerate Lead Clinical Programs and Enhance Value Creation

BioInvent International
Press release7/28/2025, 6:30 AM

Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001 at ESMO 2025

BioInvent International
Regulatory press release6/12/2025, 7:00 AM

BioInvent Presents Promising Phase 2a Monotherapy Data for BI-1808 in CTCL at EHA 2025

BioInvent International
Press release6/12/2025, 6:57 AM

BioStock: BioInvent focus on first line treatment

BioInvent International
Press release6/11/2025, 6:00 AM

BioInvent Announces Promising Phase 1 Data of BI-1206 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumors

BioInvent International
Press release6/4/2025, 6:00 AM

BioInvent Presents at PAGE 2025 a Poster Highlighting Model-Informed Early Clinical Development of anti-TNFR2 drug candidate BI-1910

BioInvent International
Press release6/2/2025, 12:58 PM

BioStock: BioInvent secured up to 30 MUSD from XOMA royalty

BioInvent International
Regulatory press release5/27/2025, 12:00 PM

XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD 30 Million

BioInvent International
Regulatory press release5/14/2025, 1:30 PM

BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the treatment of non-Hodgkin's lymphoma

BioInvent International
Regulatory press release5/14/2025, 1:30 PM

BioInvent Presents Additional CTCL Phase 2a Data for BI-1808 Monotherapy at EHA 2025

BioInvent International
Press release5/5/2025, 1:30 PM

BioInvent to Participate in Upcoming Investor Conferences

BioInvent International
Press release5/5/2025, 9:22 AM

BioInvent International AB: BioStock: BioInvent secures FDA Fast Track Designation for BI-1808

BioInvent International
Press release4/30/2025, 11:26 AM

Redeye: BioInvent Q1 2025 - Focus on BI-1808 in T-cell Lymphoma

BioInvent International
Regulatory press release4/29/2025, 3:01 PM

Resolutions at BioInvent’s Annual General Meeting 2025

BioInvent International
Press release4/29/2025, 9:55 AM

BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Cutaneous T-cell Lymphoma

BioInvent International
Regulatory press release4/29/2025, 6:00 AM

BioInvent International AB: Interim report January - March 2025

BioInvent International
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.